Dentons advises ESTEVE on the acquisition of marketing rights to Caprelsa®

Paris-Dentons Paris has advised global pharmaceutical company ESTEVE on its acquisition of the marketing rights to Caprelsa® (vandetanib) in over 50 countries - a significant milestone in the company's international expansion.

Caprelsa® is a targeted tyrosine kinase inhibitor used to treat aggressive and symptomatic medullary thyroid cancer in adults and children over the age of five. It provides a critical treatment option for patients when surgery alone is not sufficient, playing a key role in the management of this rare disease.

This transaction is fully aligned with ESTEVE's strategic transformation into a company focused on rare and ultra-rare diseases, particularly in the fields of endocrinology and onco-endocrinology.

Dentons advised on the transactional aspects of the deal with a team led by partner Anne-Laure Marcerou, alongside associates Nouçayba Soltani and Nelly Perng. The deal highlights Dentons' strength in advising on complex international transactions in the pharmaceutical sector.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com